Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 31-35

  Hasan, Eman ^a   Olusi, Samuel ^b   Al Awadhi, Adel ^b   Mokaddem, Khalid ^a   Sharma, Prem ^b   George, Sunila ^b  

^a AL AMIRI HOSPITAL   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Interleukins; Rheumatoid Arthritis; Rituximab Treatment; Vitamin D

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; METHYLPREDNISOLONE; PREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; VITAMIN D;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RHEUMATOID ARTHRITIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 84856660128     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007;66: 1137-1142.
2. Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF, Yetley EA. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88: 1519-1527.
3. Cherniack E P, Levis S, Troen BR. Hypovitaminosis D: a widespread epidemic. Geriatrics. 2008;63:24-30.
4. Cutolo M. Vitamin D and autoimmune rheumatic diseases. Rheumatolog y. 2009;48:210-212.
5. Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am. 2010;39:401-418.
6. Anderson LN, Cotterchio M, Vieth R, Knight JA. Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr. 2010;91:1699-1707.
7. Karlsson S, Olausson J, Lundh D, et al. Vitamin D and prostate cancer: the role of membrane initiated signaling pathways in prostate cancer progression. J Steroid Biochem Mol Biol. 2010;121:413-416.
8. Tse AK, Zhu GY, Wan CK, Shen XL, Yu ZL, Fong WF. 1alpha, 25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Mol Immunol. 2010;47:1728-1738.
9. Holick M F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353-373.
10. Cutolo M, Otsa K, Palino S, Yprus M, Veldi T, Seriolo B. Vitamin D involvement in rheumatoid arthritis and systemic lupus erthymatosus. Ann Rheum Dis. 2009;67:446-447.
11. Pérez-López FR. Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas. 2007;58:117-137.
12. Ritterhouse LL, Crowe SR, Niewold TB et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erthematosus. Ann Rheum Dis. 2011;(70):1569-1574.
13. Ranganathan P. Genetics of bone loss in rheumatoid arthritis-role of vitamin D receptor polymorphisms. Rheumatology. 2009;48(4): 342-346.
14. Liao K P, Alfredsson L, Karlson E W. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(3):279-283.
15. Nielen MM, van Schaardenburg D, Lems WF, et al. Vitamin D deficiency does not increase the risk of rheumatoid arthritis. Arthritis Rheum. 2006;54:3719-3720.
16. Costenbader KH, Feskanich D, Holmes M, Karlson E W, Benito-Garcia E. Vitamin D intake and risks of systemic lupus erythematosus and arthritis in women. Ann Rheum Dis. 2008;67:530-535.
17. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 2004;50:72-77.
18. Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum. 2007;56:2143-2149.
19. Turhanoǧlu AD, Güler H, Yönden Z, Aslan F, Mansuroglu A, Ozer C. The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatol Int. 2010;31: 911-914.
20. Craig SM, Yu F, Curtis JR, et al. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol. 2010;37:275-281.
21. Braun-Moscovici Y, Toledano K, Markovits D, Rozin A, Nahir AM, Balbir-Gurman A. Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int. 2011;31:493-499.
22. Cohen SB, Emery P, Greenwald M W, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-2806.
23. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68:216-221.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum.1988;31:315-324.
25. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48.
26. Shehab D, Al-Jarallah K, Moussa MA. Validation of the Arabic version of the Health Assessment Questionnaire (HAQ) in patients with rheumatoid arthritis. Rev Rhum Engl Ed. 1998;65:387-392.
27. Gannagé-Yared MH, Tohmé A, Halaby G. Hypovitaminosis D: a major worldwide public health problem. Presse Med. 2001;(30):653-658.
28. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010;95:471-478.
29. Zold E, Szodoray P, Gaal J, et al. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther. 2008;10:R123.
30. Damanhouri LH. Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Med J. 2009;30:1291-1295.
31. Mauricio D, Mandrup-Poulsen T, Nerup J. Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Diabetes Metab Rev. 1996;12:57-68.
32. Lemire JM. J Immunomodulatory actions of 1, 25-dihydroxyvitamin D3. Steroid Biochem Mol Biol. 1995;53:599-602.
33. Vilarrasa N, Vendrell J, Maravall J, et al. Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin résistance in both a healthy and morbidly obese population? Endocrinology. 2010;38: 235-242.